Shiraz University Press Molecular Biology Research Communications 2322-181X 14 3 2025 09 01 The importance of TP53 status in cancer therapy: The example of chronic lymphocytic leukemia 179 198 7935 10.22099/mbrc.2025.51477.2054 EN Regina Mirgayazova Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia Raniya Khadiullina Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia Elvina Gilyazova Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia Damir Davletshin Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia Irina Ganeeva Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia Ekaterina Zmievskaya Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia Vitaly Chasov Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia Aygul Valiullina Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia Emil Bulatov Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia Journal Article 2024 10 21 The TP53 gene encodes the tumor suppressor protein p53, which plays a critical role in genomic stability and cell cycle regulation. TP53 mutations are prevalent in approximately half of all human malignancies and are associated with poor clinical outcomes, including increased genomic instability, chemoresistance, and reduced survival rates. However, the prognostic and predictive value of TP53 status remains inconsistent across cancer types. Chronic lymphocytic leukemia (CLL) stands out as a disease where TP53 alterations have a well-established clinical significance, influencing treatment decisions and patient prognosis. In CLL, TP53 mutations and 17p deletions are strongly correlated with advanced disease stages, resistance to chemo-immunotherapy, and poor overall survival. The European Research Initiative for CLL (ERIC) has recognized TP53 status as a crucial prognostic biomarker, advocating for its routine assessment in clinical practice. Given the limitations of traditional therapies in TP53-mutated CLL, novel targeted therapies, including BCL2 and BTK inhibitors, as well as CAR-T cell therapy, are being explored to improve patient outcomes. This review provides an in-depth analysis of the evolving role of TP53 status in CLL, with a particular focus on emerging therapeutic strategies, including CAR-T cell therapy, and their potential to overcome TP53-driven treatment resistance.

https://mbrc.shirazu.ac.ir/article_7935_77ad2f9f8ec878a7783fd32a36cf98c3.pdf